Comparative Pharmacology
Head-to-head clinical analysis: LITHANE versus LITHONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LITHANE versus LITHONATE.
LITHANE vs LITHONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lithium is thought to modulate neurotransmitter release and second messenger systems, including inhibition of inositol monophosphatase and alterations in G-protein signaling, though exact mechanism in bipolar disorder is unclear.
Lithium modulates neurotransmitter activity in the central nervous system, including inhibition of inositol monophosphatase, leading to reduced phosphoinositide signaling; alters G-protein coupled receptor signaling; and inhibits glycogen synthase kinase-3 (GSK-3). It also affects ion transport, including sodium and potassium, and stabilizes neuronal excitability.
300-600 mg orally 3 times daily; usual therapeutic serum lithium level 0.6-1.2 mEq/L. Extended-release formulations given 2-3 times daily.
300-600 mg orally 2-3 times daily for acute mania; 600-1200 mg/day in divided doses for maintenance. Titrate to serum lithium level 0.8-1.2 mEq/L (acute) or 0.6-1.2 mEq/L (maintenance).
None Documented
None Documented
18-24 hours (single dose); 24-36 hours after chronic dosing; prolonged in elderly or renal impairment.
Terminal elimination half-life 18-36 hours in young adults, up to 48-72 hours in elderly or with renal impairment; steady state reached in 5-7 days.
Renal: >95% unchanged; tubular reabsorption parallels sodium; negligible biliary/fecal.
Primarily renal excretion (>95% as unchanged lithium); less than 5% excreted in feces via bile.
Category C
Category C
Mood Stabilizer
Mood Stabilizer